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Primary anorectal malignant melanoma: rare but highly lethal
malignancy
Özlem SÖNMEZ1, Ümmügül ÜYETÜRK2, Kaan HELVACI1, İbrahim TÜRKER3, Fahriye Tuğba KÖŞ4,
Lütfi DOĞAN5, Burçin BUDAKOĞLU1, Ülkü YALÇINTAŞ ARSLAN1, Ömür Berna ÇAKMAK ÖKSÜZOĞLU1

Aim: Primary anorectal malignant melanoma (MM) is a rare but highly lethal malignancy. The aim of this study was to
present an overview of the clinical features and treatment strategies in patients with anorectal MM.
Materials and methods: Nine patients who were diagnosed with anorectal MM between 1998 and 2010 were reviewed
retrospectively.
Results: The median age of the patients was 51 years (range: 28–75). The sex ratio of male to female was 1:2. The main
presenting symptom was rectal bleeding. At the time of diagnosis, 1 patient was stage IV and 8 patients were stage
III. All of the patients underwent an abdominoperineal resection. Only 1 patient received adjuvant immunotherapy
and 8 patients received palliative immunotherapy or dacarbazine and/or platinum-based chemotherapy. The median
progression-free survival was 31 weeks (range: 6–211). Sites of metastasis were the lung, liver, and brain in order of
frequency. The median overall survival was 81 weeks (range: 54–229).
Conclusion: Clear guidelines for the therapy of anorectal MM have not been established. In the treatment plan of
primary anorectal MM, multimodal treatment options involving surgery, radiotherapy, and systemic treatment with
chemotherapeutics or biological agents should be considered.
Key words: Anorectal region, malignant melanoma, treatment strategies

Introduction
Malignant melanoma (MM) is usually derived from
melanocytes producing skin pigmentation. Even
though MM constitutes only 4% of all skin malignant
neoplasms, it is responsible for 80% of the deaths due
to cutaneous neoplasms. Aside from the cutaneous
area, MM may also be observed in the eyes, mucosal
sites of the gastrointestinal system, the head and neck
area, and genital regions in the order of frequency.

There are also very rare subcategories of mucosal
MM, such as desmoplastic MM of the gingiva and
intestinal MM (1,2).
The anorectal region is the most frequently
affected part of gastrointestinal system MM. MM in
the anorectal area often develops from melanocytes
that are in the nonkeratinized squamous epithelium,
under the dentate line and transitional epithelium.
Anorectal MM constitutes 0.4% to 1.6% of all
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melanomas and less than 1% of anorectal tumors. MM
is more common in women than in men and usually
occurs in the 5th to 6th decades of life (3). Patients
with anorectal MM are usually admitted to hospitals
with the clinical symptoms of rectal bleeding, anal
mass, and changes in defecation habits (4). Anorectal
MM is frequently diagnosed in the advanced stage,
since most symptoms are nonspecific or because
a loss of time due to the treatment strategies for
hemorrhoidal disease has occurred (5).
Histopathological
examination
and
immunohistochemical studies are of great
importance in the diagnosis of anorectal MM.
Positive protein S-100, melanoma antigen HMB45, and melan-A expression strongly support the
diagnosis of melanoma (3).
Well-described surgery and adjuvant treatment
principles are available for cutaneous MM. However,
cutaneous MM treatment principles cannot fully be
applied to anorectal MM. Moreover, guidelines for
the treatment of anorectal MM are absent due to the
rareness of the disease and the inability to form large,
homogeneous series for randomized trials.
This study was presented with the purpose
of sharing our treatment experiences of patients
with anorectal MM and reviewing the clinical
specifications, follow-up, and treatment strategies of
the patients based on English-language literature.
Materials and methods
In this study, 9 anorectal MM patients, diagnosed
between 1998 and 2010, were reviewed retrospectively.
Age, sex, presenting symptoms, stage at the time of
diagnosis, sites of metastasis, surgery, and treatment
modalities were recorded.
Results
The median age of the 9 patients was 51 years (range:
28–75). Six patients (67%) were female. Six patients
(67%) presented with rectal bleeding, 2 with sensation of anorectal mass, and 1 with anal pain. At the
time of diagnosis, 1 patient had stage IV disease and
8 patients had stage III disease with lymph node metastasis. All of the patients, including the metastatic
patient, had undergone an abdominoperineal resec1514

tion (APR). Only one patient received adjuvant immunotherapy.
The median follow-up was 81 weeks (range: 54–
229). All of the patients developed distant metastasis
within the follow-up period. The median progression-free survival (PFS) was 31 weeks (range: 6–211).
Visceral sites of the metastasis were the lung, liver,
and brain in the order of frequency. All but one of
the patients died during the follow-up period. The
median overall survival (OS) was 81 weeks (range:
54–229).
The patients received a minimum of 1 and a
maximum of 4 lines of palliative chemotherapy or
immunotherapy. In the metastatic setting, 4 patients
(44.4%) received dacarbazine (DTIC) and cisplatin,
1 received temozolomide (TMZ), 1 received DTIC
alone, and 3 received interferon (IFN) as the firstline treatment. In the second line, 4 patients (80%)
received TMZ and 1 received paclitaxel and carboplatin (PC). In the third line, 3 patients received PC.
In the fourth line, 1 patient received IFN (33.3%), 1
received DTIC, and 1 received ipilimumab with an
early access program.
Palliative radiation therapy was used for 4 patients (1 (25%) for brain metastasis, 1 for brain and
intraabdominal lymph node metastasis, and 2 for the
primary site of the rectum).
The general characteristics of the patients are
shown in the Table.
Discussion
Anorectal MM is an aggressive neoplasm seen
in the 5th and 6th decades of life with a female
preponderance. The most frequent symptom leading
to diagnosis is rectal bleeding. The feeling of an
anorectal mass, anal pain, discharge, and/or itching
may be among the other initial symptoms. Patients
are unusually misdiagnosed as having hemorrhoidal
disease due to these nonspecific symptoms; thus, the
main diagnosis is frequently delayed (3,5).
In this study, similar to in the literature, the median
age of the entire cohort was 51 and the female-tomale ratio was 2:1, with the most frequent initial
symptom being rectal bleeding. In the only patient
who was presented in the upfront metastatic stage,
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Table. General characteristics of the patients.
Case 1

Case 2

Case 3

Case 4

Case 5

Case 6

Case 7

Case 8

Case 9

Sex

M

M

F

F

M

F

F

F

F

Age

43

75

56

56

51

65

42

28

46

Anal pain

Rectal
bleeding

Rectal mass
sense

Rectal
bleeding

Rectal
bleeding

Rectal
bleeding

Rectal mass
sense

Rectal
bleeding

Rectal
bleeding

3

3

3

3

3

3

4

3

3

23 weeks

63 weeks

211 weeks

6 weeks

31 weeks

8 weeks

Metastatic
at the
beginning

50 weeks

69 weeks

Initial
complaints
Stage
Time from op.
to met.
Adj. T.

IFN

First line of
Pal. T.

Cisp +
DTIC

DTIC

Cisp +
DTIC

Cisp +
DTIC

Cisp +
DTIC

IFN

IFN

IFN

TMZ

Second line of
Pal. T.

TMZ

PC

-

-

TMZ

TMZ

TMZ

-

-

Third line of
Pal. T.

-

-

-

-

PC

PC

PC

-

-

Fourth line of
Pal. T.

-

-

-

-

IFN

Ipilimumab

DTIC

-

-

To anal
mass

To anal
mass

-

-

To abd. mass
and brain

-

To brain

Lung,
liver,
local

Liver,
local

Inguinal lap,
abd.
lap

Lung

Liver,
abd. lap,
brain

Lung,
liver,

55
weeks

81
weeks

229
weeks

54
weeks

137
weeks

Deceased

Deceased

Deceased

Deceased

Deceased

RT
(pal.)

Met. regions
Follow-up time
Last state

-

Liver,
brain

Lung

Lung

78
weeks

69
weeks

122
weeks

121
weeks

Deceased

Deceased

Deceased

Alive

Abd: abdominal, Adj: adjuvant, M: male, F: female, Lap: lymphadenopathy, Ing: inguinal, IFN: interferon, DTIC: dacarbazine, Cisp:
cisplatin, TMZ: temozolamide, PC: paclitaxel–carboplatin, Pal: palliative, RT: radiotherapy, Rec: recurrence, Op: operation, Met:
metastasis, T: treatment.

the diagnosis was delayed because of the symptoms
resembling hemorrhoidal disease.
The reported incidence of locoregional lymph
node metastasis at the time of diagnosis was 61% in
the anorectal area, 21% in the head and neck area,
23% in the genital area, 11% in the urinary system,

and 9% in skin/cutaneous melanoma (6). Parallel to
the literature, 8 of the 9 anorectal MM patients in the
present study had locoregional metastasis. Therefore,
it can be concluded that the prognosis of anorectal
MM is noticeably worse than both adenocarcinoma
of the same region and MM of the cutaneous origin.
1515
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In addition to the advanced stage at the time of
diagnosis, the rich vascularity of the rectum and
the biological aggressiveness of the tumor were also
blamed for the poor prognosis (7).
The traditional treatment of anorectal MM is usually based on surgery. Surgical treatment options
include radical operations such as APR, pelvic exenteration, or conservative methods such as local excision (LE). Wide LE is recommended as the primary
therapy if negative resection margins can be achieved
(8). Iddings et al. (9), who presented the largest series
in this respect with 183 patients, reported that radical
operations were gradually decreasing in number and
were the less preferred method of surgery. There are
numerous studies searching for the effects of radical
and conservative methods on survival. Most of these
studies reported that radical resections did not contribute to prolonged survival (8,10,11). However, a
poor prognosis was confirmed despite the curative
surgical approach of anorectal MM in a retrospective
analysis with either APR or LE (12). In addition, one
must not forget that survival is determined by distant metastasis. LE may prevent a gross surgery and
complications due to colostomy, but it is evident that
there is no choice other than radical surgery in diseases appearing with serious bleeding or obstructive
large or anal sphincter invasive tumors. We speculate
that APR was obligatory in our patients because of
quite serious anorectal grievances such as bleeding
and advanced staging. Determination of the optimal
surgery option should aim not only to extend the lifetime but also to increase the quality of life.

Many agents have been tried in the adjuvant
treatment of cutaneous MM, but a clinical benefit
was only obtained with alpha-IFN 2b and pegylated
forms of IFN (14). In this study, 69 weeks of diseasefree survival was obtained in 1 patient, to whom IFN
was given in the adjuvant setting.
Chemotherapy is generally used for palliative
purposes in advanced stages of MM and survival
after diagnosis is quite short. There are standard
systematic treatment options defined in advanced
cutaneous MM patients, including cisplatin,
vinblastine, DTIC, IFN, and interleukin-2. In many
studies conducted in the last decade, single agent or
combination chemotherapy regimens for advanced
stages of skin MMs were tried; however, DTIC has
still been accepted as the standard of care (15).
Because of the limited number of studies, there is no
standard treatment for mucosal MM (16). DTIC was
used as a single agent or in combination as the first
line of treatment at the metastatic stage in our series.

Recent studies revealed that adding locoregional
radiotherapy (5 × 6 Gy) to sphincter-sparing surgery
provided less loss of function when compared to APR,
and similar locoregional control was obtained (13).
In this study, APR was applied to all of the patients;
thus, radiation therapy was not used for local control.

Another alternative is an orally bioavailable drug,
TMZ. It does not require hepatic activation and
quickly passes through the blood–brain barrier. In
a phase III study by Middleton et al. (17), an equal
efficacy of TMZ in comparison to DTIC was found
in advanced stage metastatic cutaneous MM patients.
PFS in patients treated with TMZ was 1.9 months in
comparison to 1.5 months with DTIC (P = 0.012;
HR, 1.37; 95% CI 1.07–1.75). Another combination
chemotherapy commonly used in advanced stage
cutaneous MM is the PC combination. Rao et al. (18)
used PC in the second line of treatment of cutaneous
MM and found a median PFS and OS of 3 and 7.8
months, respectively. In this study, 1 patient who
received PC in the second line of treatment showed 7
weeks of PFS, and 3 patients who received PC in the
third line of treatment showed 26, 13, and 9 weeks
of PFS.

While standard staging and adjuvant treatment
suggestions for skin MMs are specified, standard
guidelines for staging and adjuvant treatment
protocols for anorectal MM are not specified.
Actually, it is already known that anorectal MM is
quite radioresistant and does not respond well to
chemotherapy. Despite having no proven benefit,
adjuvant treatment protocols used for skin MMs are
not infrequently used for anorectal MM patients.

Yeh et al. (16) used a combination regimen with
cisplatin as the third line of treatment after colostomy
and radiotherapy, TMZ, and liposomal doxorubicin
for a 49-year-old female anal mucosal melanoma
patient with complete colonic obstruction and
multiple distant organ metastases. After the second
course, more than 50% regression was observed in
the metastases in all regions, and the analgesic need
was minimized and the quality of life of the patient
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improved with minimal residual disease at the 12th
month of treatment.
Research regarding MM treatment has
accelerated in recent years. Ipilimumab, which is
an immunomodulatory monoclonal antibody, was
developed against an antigen on T lymphocytes.
Common T lymphocyte antigen-4, an antigen that is
related to cytotoxic T lymphocytes, has a pressurizing
function on cytotoxic T cells. Blocking this antigen
results in cytotoxic T cells’ movement against cancer
cells. A 3-arm phase III randomized study by Hodi
et al. (19) demonstrated that ipilimumab increased
survival in 674 pretreated patients with advanced
stage cutaneous MM.
Ipilimumab is accepted as an alternative treatment
option for patients with resistant cutaneous MM, but
its place in primary anorectal MM treatment should
be further studied.
In a study of 17 anorectal MM patients, the
median OS was reported to be 32 weeks. In that study,

7 patients were treated with radical surgery, and only
2 patients received adjuvant immunotherapy (20).
The reason for the longer OS data of the present study
may depend on the application of radical surgery to
all of the patients or the adding of more systemic
palliative treatment lines (like PC or ipilimumab)
before following up with the best supportive care.
Presently, advanced anorectal MM remains
an incurable disease, and despite the use of
multidisciplinary strategies (radical surgery,
immunotherapy, chemotherapy, and radiotherapy),
it remains a fatal disease. Current guidelines do not
include a definitive staging or standard treatment
options for anorectal MM. As a result, treatment of
individual cases is based on retrospective studies
including a limited number of cases. Surgery
still remains the mainstay of the treatment.
Adding radiotherapy, systemic treatment with
immunotherapeutics and/or chemotherapeutics, or
biological agents to surgery should be considered
since the prognosis of anorectal MM is dismal.
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